
Zevra Therapeutics Investor Relations Material
Latest events

Q1 2025
Zevra Therapeutics
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Zevra Therapeutics Inc
Access all reports
Zevra Therapeutics Inc., previously known as KemPharm Inc., is a biopharmaceutical company specializing in the development of proprietary prodrugs for the treatment of serious medical conditions, with a focus on rare diseases. The company utilizes its Ligand Activated Therapy technology to create enhanced versions of FDA-approved drugs and new compounds for potential new disease indications. Zevra's product pipeline includes KP1077, designed for the treatment of idiopathic hypersomnia (IH) and narcolepsy, and KP879 for stimulant use disorder, both in Phase II clinical trials. Additionally, Zevra has FDA-approved products like AZSTARYS for attention deficit hyperactivity disorder and APADAZ, a combination treatment containing a prodrug of hydrocodone and acetaminophen. The company is headquartered in Celebration, Florida, and its shares are listed on the NASDAQ.
Key slides for Zevra Therapeutics Inc


Q2 2024
Zevra Therapeutics Inc


Corporate Presentation
Zevra Therapeutics Inc
Latest articles
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
)
Eli Lilly: The Pharma Giant Behind Mounjaro and Zepbound
Eli Lilly's journey from insulin pioneer to global pharma giant, leading innovation in diabetes, obesity, and the future of metabolic health.
30 Jun 2025
Ticker symbol
ZVRA
Country
🇺🇸 United States